SCHEMBL23792005

SCHEMBL23792005

CC(C)c1sc(Nc2ncc(Cc3ccccc3)cc2C(=O)O)nc1-c1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 3/20 0.43
▸ RORB Q92753 2/20 0.40
▸ PPARG P37231 2/20 0.36
▸ PPARA Q07869 1/20 0.36
▸ XIAP P98170 1/20 0.35
▸ RORC P51449 3/20 0.35
▸ MDM2 Q00987 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ KDM4A O75164 1/20 0.34
▸ KDM5A P29375 1/20 0.34
▸ KDM5B Q9UGL1 1/20 0.34
▸ NR1H2 P55055 1/20 0.34
▸ NR1H3 Q13133 1/20 0.34
▸ PRSS12 P56730 1/20 0.34
▸ NOTUM Q6P988 1/20 0.34
▸ LIMK1 P53667 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23792003 0.90 DHODH (0.38) DHODHXIAPRORC
SCHEMBL23782401 0.89 DHODH (0.45) DHODHRORBPPARGRORCKDR
SCHEMBL30173772 0.89 DHODH (0.45) DHODHRORBPPARGRORCKDR
SCHEMBL23791998 0.84 DHODH (0.46) DHODHRORBKDRNOTUM
SCHEMBL23792008 0.83 DHODH (0.39) DHODHRORBBLMKDR
SCHEMBL23791736 0.79 DHODH (0.47) DHODHRORBRORCKDM4EPRSS12
SCHEMBL23782403 0.78 NOTUM (0.43) DHODHRORBKDM4EBLMKDR
SCHEMBL30176219 0.78 NOTUM (0.43) DHODHRORBKDM4EBLMKDR
SCHEMBL23782375 0.78 DHODH (0.41) DHODHRORC
SCHEMBL23782602 0.78 DHODH (0.47) DHODHRORBRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 DHODH 3236/4885RORB 2834/4885PPARG 4693/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 DHODH 3236/4885RORB 2834/4885PPARG 4693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback